Comparison of Three Cellular Assays to Predict the Course of CMV Infection in Liver Transplant Recipients
To estimate protection from cytomegalovirus (CMV) replication after solid organ transplantation, CMV serology has been considered insufficient and thus CMV immunity is increasingly assessed by cellular in vitro methods. We compared two commercially available IFN-γ ELISpot assays (T-Track CMV and T-SPOT.CMV) and an IFN-γ ELISA (QuantiFERON-CMV). Currently, there is no study comparing these three assays. The assays were performed in 56 liver transplant recipients at the end of antiviral prophylaxis and one month thereafter. In CMV high- or intermediate-risk patients the two ELISpot assays showed significant correlation (p < 0.0001, r > 0.6) but the correlation of the ELISpot assays with QuantiFERON-CMV was weaker. Results of both ELISpot assays were similarly predictive of protection from CMV-DNAemia ≥500 copies/mL [CMV pp65 T-SPOT.CMV at the end of prophylaxis: area under curve (AUC) = 0.744, cut-off 142 spot forming units (SFU), sensitivity set to 100%, specificity 46%; CMV IE-1 T-Track CMV at month 1: AUC = 0.762, cut-off 3.5 SFU, sensitivity set to 100%, specificity 59%]. The QuantiFERON-CMV assay was inferior, reaching a specificity of 23% when setting the sensitivity to 100%. In conclusion, both CMV-specific ELISpot assays appear suitable to assess protection from CMV infection/reactivation in liver transplant recipients.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
---|---|
Enthalten in: |
Vaccines - 9(2021), 2 vom: 25. Jan. |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Gliga, Smaranda [VerfasserIn] |
---|
Links: |
---|
Themen: |
ELISA |
---|
Anmerkungen: |
Date Revised 28.02.2021 published: Electronic Citation Status PubMed-not-MEDLINE |
---|
doi: |
10.3390/vaccines9020088 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM32065835X |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM32065835X | ||
003 | DE-627 | ||
005 | 20231225174041.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.3390/vaccines9020088 |2 doi | |
028 | 5 | 2 | |a pubmed24n1068.xml |
035 | |a (DE-627)NLM32065835X | ||
035 | |a (NLM)33504093 | ||
035 | |a (PII)88 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Gliga, Smaranda |e verfasserin |4 aut | |
245 | 1 | 0 | |a Comparison of Three Cellular Assays to Predict the Course of CMV Infection in Liver Transplant Recipients |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 28.02.2021 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status PubMed-not-MEDLINE | ||
520 | |a To estimate protection from cytomegalovirus (CMV) replication after solid organ transplantation, CMV serology has been considered insufficient and thus CMV immunity is increasingly assessed by cellular in vitro methods. We compared two commercially available IFN-γ ELISpot assays (T-Track CMV and T-SPOT.CMV) and an IFN-γ ELISA (QuantiFERON-CMV). Currently, there is no study comparing these three assays. The assays were performed in 56 liver transplant recipients at the end of antiviral prophylaxis and one month thereafter. In CMV high- or intermediate-risk patients the two ELISpot assays showed significant correlation (p < 0.0001, r > 0.6) but the correlation of the ELISpot assays with QuantiFERON-CMV was weaker. Results of both ELISpot assays were similarly predictive of protection from CMV-DNAemia ≥500 copies/mL [CMV pp65 T-SPOT.CMV at the end of prophylaxis: area under curve (AUC) = 0.744, cut-off 142 spot forming units (SFU), sensitivity set to 100%, specificity 46%; CMV IE-1 T-Track CMV at month 1: AUC = 0.762, cut-off 3.5 SFU, sensitivity set to 100%, specificity 59%]. The QuantiFERON-CMV assay was inferior, reaching a specificity of 23% when setting the sensitivity to 100%. In conclusion, both CMV-specific ELISpot assays appear suitable to assess protection from CMV infection/reactivation in liver transplant recipients | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a ELISA | |
650 | 4 | |a ELISpot | |
650 | 4 | |a human cytomegalovirus | |
650 | 4 | |a interferon-γ | |
650 | 4 | |a liver transplantation | |
650 | 4 | |a prediction | |
650 | 4 | |a reactivation | |
700 | 1 | |a Fiedler, Melanie |e verfasserin |4 aut | |
700 | 1 | |a Dornieden, Theresa |e verfasserin |4 aut | |
700 | 1 | |a Achterfeld, Anne |e verfasserin |4 aut | |
700 | 1 | |a Paul, Andreas |e verfasserin |4 aut | |
700 | 1 | |a Horn, Peter A |e verfasserin |4 aut | |
700 | 1 | |a Herzer, Kerstin |e verfasserin |4 aut | |
700 | 1 | |a Lindemann, Monika |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Vaccines |d 2012 |g 9(2021), 2 vom: 25. Jan. |w (DE-627)NLM239212347 |x 2076-393X |7 nnns |
773 | 1 | 8 | |g volume:9 |g year:2021 |g number:2 |g day:25 |g month:01 |
856 | 4 | 0 | |u http://dx.doi.org/10.3390/vaccines9020088 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 9 |j 2021 |e 2 |b 25 |c 01 |